Kirsten rat sarcoma viral oncogene homolog G12V mutant peptide antigen (KRAS G12V)

The KRAS G12V mutant peptide antigen is a tumor-specific neoantigen derived from the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein, specifically featuring a glycine-to-valine substitution at codon 12 (NIH, 2023; PatSnap, 2024). This mutation is a frequent driver in aggressive malignancies, including pancreatic, colorectal, and lung cancers, where it leads to constitutive activation of downstream signaling pathways like MAPK and PI3K (NIH, 2023; ResearchGate, 2025). As a neoantigen, the G12V peptide is processed and presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules, making it a highly specific target for the immune system (NIH, 2024; BioDragons, 2023). Therapeutic strategies targeting this antigen include cancer vaccines such as ELI-002 and mRNA-5671, as well as adoptive T-cell therapies like TCR-T and CAR-T, which aim to stimulate or provide T cells that selectively recognize and destroy KRAS G12V-expressing cells (ResearchGate, 2025; ISF, 2024). Because the mutation is absent in healthy tissues, targeting this peptide offers a high degree of tumor specificity, although challenges such as HLA restriction and immune evasion through antigen loss remain significant hurdles in clinical development (BioRxiv, 2024; MyrioTX, 2025; NIH, 2025).

Other names

KRAS G12V neoantigenKRAS G12V peptideKRAS G12V pMHCKRAS G12V mutant epitopeG12V mutant KRAS peptide

Vaccine-mediated induction of T-cell responses, TCR-T mediated direct cytotoxicity, CAR-T mediated tumor cell lysis, and cytokine-induced immune activation.